The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Zogenix, Inc. (NASDAQ: ZGNX) who purchased shares between February 6, 2019 and April 8, 2019. The action, which was filed in the United States District Court for the Northern District of California, alleges that the Company violated federal securities laws.
(i) Zogenix’s NDA for FINTEPLA contained inadequate non-clinical data and an incorrect version of a clinical dataset; (ii) consequently, Zogenix’s NDA for FINTEPLA was unlikely to gain FDA approval; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Shareholders have until June 11, 2019 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
To learn more and keep informed, complete this form >